Bictegravir/lenacapavir (Bixlenvo) vs Elvitegravir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

Bictegravir/lenacapavir (Bixlenvo)

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Partial signal

NCT05502341 · Phase 2/3 · active, not recruiting

This was a randomized, active-controlled trial in 557 people in its Phase 3 part, but it was open-label, so participants and investigators knew which treatment each person received. Its primary endpoint, the proportion with detectable HIV-1 RNA at week 48, is an objective laboratory measure, and bictegravir/lenacapavir met the non-inferiority goal against continued complex regimens.

Next expected readout: July 2028 · NCT07908446 (registry estimate)

Reported efficacy

Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm; Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). (met)

Result source: NCT05502341

Elvitegravir · Stribild

Marketed by Gilead Sciences and partners

Approved in HIVsmall molecule
Partial signal

NCT01095796 · Phase 3 · completed

Participants were randomized and quadruple-blinded to Stribild or active-controlled Atripla, with 348 and 352 treated participants analyzed, respectively. The primary week-48 virologic endpoint met the prespecified non-inferiority criterion, but HIV-1 RNA suppression is a surrogate endpoint rather than a hard clinical or endoscopic outcome.

Reported efficacy

The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1% (met)

Result source: NCT01095796

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBictegravir/​lenacapavir (Bixlenvo)Elvitegravir
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT0653265687.6% vs 84.1%vs Atriplawk 48 · n 348NCT01095796
34 other results
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.1% vs 92.8% wk 48 · n 435 · Phase 3 · primary NCT01780506
  • 59% vs 57.8% wk 48 · n 351 · Phase 3 · primary NCT00708162
  • 93.8% vs 87.1% wk 48 · n 290 · Phase 3 · primary NCT01475838
  • 93.4% vs 88.1% wk 48 · n 290 · Phase 3 · primary NCT01495702
  • 89.5% vs 86.8% wk 48 · n 353 · Phase 3 · primary NCT01106586
  • 80.2% vs 75.3% wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 86.9% vs 83.1% wk 144 · n 435 · Phase 3 · secondary NCT01780506
  • 77.6% vs 74.6% wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 84.2% vs 81.5% wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 89.2% vs 88.2% wk 96 · n 435 · Phase 3 · secondary NCT01780506
  • 47.6% vs 45% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 52.4% vs 53% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 53.6% vs 56.4% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 86.9% vs 69.8% wk 96 · n 290 · Phase 3 · secondary NCT01475838
  • 86.6% vs 80.4% wk 96 · n 290 · Phase 3 · secondary NCT01495702
  • 83.3% vs 82.3% wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 85.9% vs 83.2% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 88.8% vs 85.5% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 59.8% vs 57.5% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 61% vs 60.7% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 86.1% vs 84.8% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 91.5% vs 88.5% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 76.1% vs 78.1% wk 192 · n 71 · Phase 3 · secondary NCT01095796
  • 78.4% vs 73.1% wk 192 · n 74 · Phase 3 · secondary NCT01106586
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · primary NCT00869557
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 89.6% vs 87% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 91.7% vs 82.6% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · secondary NCT00869557
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT06532656—Not reported
CD4 count, change (week 48)—Trial running · NCT06532656360 vs 328vs Atriplawk 192 · n 348NCT01095796
26 other results
  • 338 vs 340 wk 192 · n 353 · Phase 3 · secondary NCT01106586
  • 321 vs 300 wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 323 vs 310 wk 144 · n 379 · Phase 3 · secondary NCT01780506
  • 280 vs 293 wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 295 vs 273 wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 60 vs 42 wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 285 vs 271 wk 96 · n 395 · Phase 3 · secondary NCT01780506
  • 205 vs 198 wk 96 · n 231 · Phase 3 · secondary NCT00708162
  • 61 vs 71 wk 96 · n 255 · Phase 3 · secondary NCT01475838
  • 83 vs 101 wk 96 · n 256 · Phase 3 · secondary NCT01495702
  • 256 vs 261 wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 239 vs 206 wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 235 vs 221 wk 48 · n 413 · Phase 3 · secondary NCT01780506
  • 207 vs 211 wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 138 vs 147 wk 48 · n 267 · Phase 3 · secondary NCT00708162
  • 40 vs 32 wk 48 · n 270 · Phase 3 · secondary NCT01475838
  • 56 vs 58 wk 48 · n 270 · Phase 3 · secondary NCT01495702
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 240 vs 166 wk 48 · n 45 · Phase 2 · secondary NCT00869557
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 161 vs 117 wk 24 · n 44 · Phase 2 · secondary NCT00869557

HIV-1 RNA below 50 copies/mL (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
Elvitegravir
87.6% vs 84.1%vs Atriplawk 48 · n 348NCT01095796
34 other results
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.1% vs 92.8% wk 48 · n 435 · Phase 3 · primary NCT01780506
  • 59% vs 57.8% wk 48 · n 351 · Phase 3 · primary NCT00708162
  • 93.8% vs 87.1% wk 48 · n 290 · Phase 3 · primary NCT01475838
  • 93.4% vs 88.1% wk 48 · n 290 · Phase 3 · primary NCT01495702
  • 89.5% vs 86.8% wk 48 · n 353 · Phase 3 · primary NCT01106586
  • 80.2% vs 75.3% wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 86.9% vs 83.1% wk 144 · n 435 · Phase 3 · secondary NCT01780506
  • 77.6% vs 74.6% wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 84.2% vs 81.5% wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 89.2% vs 88.2% wk 96 · n 435 · Phase 3 · secondary NCT01780506
  • 47.6% vs 45% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 52.4% vs 53% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 53.6% vs 56.4% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 86.9% vs 69.8% wk 96 · n 290 · Phase 3 · secondary NCT01475838
  • 86.6% vs 80.4% wk 96 · n 290 · Phase 3 · secondary NCT01495702
  • 83.3% vs 82.3% wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 85.9% vs 83.2% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 88.8% vs 85.5% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 59.8% vs 57.5% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 61% vs 60.7% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 86.1% vs 84.8% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 91.5% vs 88.5% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 76.1% vs 78.1% wk 192 · n 71 · Phase 3 · secondary NCT01095796
  • 78.4% vs 73.1% wk 192 · n 74 · Phase 3 · secondary NCT01106586
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · primary NCT00869557
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 89.6% vs 87% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 91.7% vs 82.6% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · secondary NCT00869557

HIV-1 RNA 50 copies/mL or more (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
Elvitegravir
—Not reported

CD4 count, change (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
Elvitegravir
360 vs 328vs Atriplawk 192 · n 348NCT01095796
26 other results
  • 338 vs 340 wk 192 · n 353 · Phase 3 · secondary NCT01106586
  • 321 vs 300 wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 323 vs 310 wk 144 · n 379 · Phase 3 · secondary NCT01780506
  • 280 vs 293 wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 295 vs 273 wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 60 vs 42 wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 285 vs 271 wk 96 · n 395 · Phase 3 · secondary NCT01780506
  • 205 vs 198 wk 96 · n 231 · Phase 3 · secondary NCT00708162
  • 61 vs 71 wk 96 · n 255 · Phase 3 · secondary NCT01475838
  • 83 vs 101 wk 96 · n 256 · Phase 3 · secondary NCT01495702
  • 256 vs 261 wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 239 vs 206 wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 235 vs 221 wk 48 · n 413 · Phase 3 · secondary NCT01780506
  • 207 vs 211 wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 138 vs 147 wk 48 · n 267 · Phase 3 · secondary NCT00708162
  • 40 vs 32 wk 48 · n 270 · Phase 3 · secondary NCT01475838
  • 56 vs 58 wk 48 · n 270 · Phase 3 · secondary NCT01495702
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 240 vs 166 wk 48 · n 45 · Phase 2 · secondary NCT00869557
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 161 vs 117 wk 24 · n 44 · Phase 2 · secondary NCT00869557
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Bictegravir/lenacapavir (Bixlenvo)
Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). NCT05502341 · Phase 2/3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Bictegravir/lenacapavir (Bixlenvo): 0 of 4 rows · Elvitegravir: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricElvitegravir
Dropout rate
83.6%a
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 38 more results
22.2%
NCT02477527 · Phase 4 · registry result, not featured evidence
—DSG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
6.3%Delayed Switch Group (DSG)
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 0-24
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
5.1%Immediate Switch Group (ISG)
NCT02397096 · Phase 3 · registry result, not featured evidence
5.1%E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3 · registry result, not featured evidence
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
20%E/C/F/TAF
NCT01797445 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3 · registry result, not featured evidence
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
5.4%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Double-Blind: E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
16%E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—Open-Label: E/C/F/TAF to E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
43.2%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
12.3%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
12.1%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
10.2%
NCT01475838 · Phase 3 · registry result, not featured evidence
—All Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
8.9%Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
—Stribild (Randomized Phase)
NCT01495702 · Phase 3 · registry result, not featured evidence
80.7%
NCT01106586 · Phase 3 · registry result, not featured evidence
0%
NCT01533259 · Phase 3 · registry result, not featured evidence
14%
NCT01721109 · Phase 2/3 · registry result, not featured evidence
5.3%
NCT01497899 · Phase 2 · registry result, not featured evidence
6.3%
NCT00869557 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
2.5%a
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 38 more results
—
NCT02477527 · Phase 4 · registry result, not featured evidence
—DSG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
0.4%Delayed Switch Group (DSG)
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 0-24
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
1.6%Immediate Switch Group (ISG)
NCT02397096 · Phase 3 · registry result, not featured evidence
0.7%E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3 · registry result, not featured evidence
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
0.7%E/C/F/TAF
NCT01797445 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3 · registry result, not featured evidence
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
0.9%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Double-Blind: E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0.9%E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—Open-Label: E/C/F/TAF to E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
2.2%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
4.1%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
6.1%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
2%
NCT01475838 · Phase 3 · registry result, not featured evidence
—All Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
0.7%Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
—Stribild (Randomized Phase)
NCT01495702 · Phase 3 · registry result, not featured evidence
2.5%
NCT01106586 · Phase 3 · registry result, not featured evidence
—
NCT01533259 · Phase 3 · registry result, not featured evidence
—
NCT01721109 · Phase 2/3 · registry result, not featured evidence
0.9%
NCT01497899 · Phase 2 · registry result, not featured evidence
—
NCT00869557 · Phase 2 · registry result, not featured evidence
Serious AEs
19.8%a
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 38 more results
0%
NCT02477527 · Phase 4 · registry result, not featured evidence
1.9%DSG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
6.4%DSG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
4.5%DSG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
2.3%DSG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
—Delayed Switch Group (DSG)
NCT02397096 · Phase 3 · registry result, not featured evidence
2.9%ISG Base Study Weeks 0-24
NCT02397096 · Phase 3 · registry result, not featured evidence
2.6%ISG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
9.3%ISG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
4.3%ISG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
3.6%ISG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
—Immediate Switch Group (ISG)
NCT02397096 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
3%Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3 · registry result, not featured evidence
5.2%Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3 · registry result, not featured evidence
8.2%Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF
NCT01797445 · Phase 3 · registry result, not featured evidence
12.5%E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3 · registry result, not featured evidence
2.8%Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3 · registry result, not featured evidence
1.7%Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3 · registry result, not featured evidence
5.3%DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
8.7%Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
9.1%
NCT02616783 · Phase 3 · registry result, not featured evidence
16.8%Double-Blind: E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0%Open-Label: E/C/F/TAF to E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
20.6%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
15.1%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
18.2%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
8.2%
NCT01475838 · Phase 3 · registry result, not featured evidence
8.9%All Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
—Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
8.2%Stribild (Randomized Phase)
NCT01495702 · Phase 3 · registry result, not featured evidence
16.4%
NCT01106586 · Phase 3 · registry result, not featured evidence
2.1%
NCT01533259 · Phase 3 · registry result, not featured evidence
10%
NCT01721109 · Phase 2/3 · registry result, not featured evidence
10.7%
NCT01497899 · Phase 2 · registry result, not featured evidence
4.2%
NCT00869557 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
diarrhoea 26.7%
upper respiratory tract infection 26.4%
nausea 23%
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 31 more results
headache 6.7%
diarrhoea 4.3%
nasopharyngitis 4.3%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.4%
headache 6.4%
diarrhoea 5.4%
NCT02397096 · Phase 3 · registry result, not featured evidence
covid-19 3.9%
headache 1.9%
back pain 1.3%
NCT02397096 · Phase 3 · registry result, not featured evidence
covid-19 7%
arthralgia 0%
back pain 0%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.4%
headache 6.5%
diarrhoea 4.5%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.4%
back pain 3.7%
diarrhoea 3%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 12.8%
headache 5.5%
arthralgia 5.3%
NCT02397096 · Phase 3 · registry result, not featured evidence
back pain 2.3%
arthralgia 1.7%
nasopharyngitis 1.7%
NCT02397096 · Phase 3 · registry result, not featured evidence
covid-19 8.3%
arthralgia 1.2%
diarrhoea 1.2%
NCT02397096 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 7.4%
nasopharyngitis 5.2%
diarrhoea 4.4%
NCT01815736 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 6.1%
diarrhoea 5.2%
nasopharyngitis 4.7%
NCT01815736 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.5%
diarrhoea 11.4%
nasopharyngitis 10%
NCT01815736 · Phase 3 · registry result, not featured evidence
diarrhoea 23%
headache 22.7%
upper respiratory tract infection 20.2%
NCT01797445 · Phase 3 · registry result, not featured evidence
nasopharyngitis 3.5%
headache 2.8%
arthralgia 1.4%
NCT01797445 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.2%
cough 2.5%
syphilis 2.5%
NCT01797445 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 14.6%
headache 11%
anaemia 7.3%
NCT01705574 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.3%
headache 17%
nausea 14.9%
NCT01705574 · Phase 3 · registry result, not featured evidence
nasopharyngitis 10.9%
back pain 8.2%
diarrhoea 7.3%
NCT02616783 · Phase 3 · registry result, not featured evidence
diarrhoea 25.7%
upper respiratory tract infection 21.1%
nausea 16.8%
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
cough 4.4%
syphilis 4.4%
upper respiratory tract infection 3.3%
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
diarrhoea 33.9%
upper respiratory tract infection 21.2%
headache 13.8%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
upper respiratory tract infection 20.5%
nasopharyngitis 19.2%
bronchitis 13.7%
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 36.4%
insomnia 21.2%
headache 18.2%
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 13.3%
upper respiratory tract infection 9.9%
diarrhoea 9.2%
NCT01475838 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 11.3%
diarrhoea 10.2%
nasopharyngitis 10.2%
NCT01495702 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 11.3%
diarrhoea 10.3%
nasopharyngitis 10.3%
NCT01495702 · Phase 3 · registry result, not featured evidence
diarrhoea 28%
upper respiratory tract infection 24.4%
nausea 22.7%
NCT01106586 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 20.8%
insomnia 12.5%
anxiety 10.4%
NCT01533259 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 36%
headache 24%
vomiting 20%
NCT01721109 · Phase 2/3 · registry result, not featured evidence
nausea 22.3%
diarrhoea 17%
fatigue 16.1%
NCT01497899 · Phase 2 · registry result, not featured evidence
diarrhoea 27.1%
fatigue 16.7%
headache 14.6%
NCT00869557 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 34 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Elvitegravir

HIV-1 RNA Less Than 50 Copies 87.6% (n=348) vs 84.1% (n=352) Atripla @ 48wk
responder rate · % of participants
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 34 more results
84.2% (n=348) vs 81.5% (n=352) Atripla @ 96wk
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
80.2% (n=348) vs 75.3% (n=352) Atripla @ 144wk
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
76.1% (n=71) vs 78.1% (n=73) Atripla @ 192wk
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
85.9% (n=348) vs 83.2% (n=352) Atripla @ 48wk
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
88.8% (n=348) vs 85.5% (n=352) Atripla @ 48wk
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
92.8% (n=959) vs 89.1% (n=477) Baseline Treatment Regimen (SBR) @ 96wk
NCT01815736 · Phase 3 · registry result, not featured evidence
91.6% (n=431) vs 88.5% (n=435) E/C/F/TDF @ 48wk
NCT01797445 · Phase 3 · registry result, not featured evidence
84% (n=431) vs 82.3% (n=435) E/C/F/TDF @ 96wk
NCT01797445 · Phase 3 · registry result, not featured evidence
87.2% (n=289) vs 80.8% (n=286) ATV+RTV+TVD @ 48wk
NCT01705574 · Phase 3 · registry result, not featured evidence
93.1% (n=435) vs 92.8% (n=432) E/C/F/TDF @ 48wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
89.2% (n=435) vs 88.2% (n=432) E/C/F/TDF @ 96wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
86.9% (n=435) vs 83.1% (n=432) E/C/F/TDF @ 144wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
59% (n=351) vs 57.8% (n=351) Raltegravir @ 48wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
47.6% (n=351) vs 45% (n=351) Raltegravir @ 96wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
59.8% (n=351) vs 57.5% (n=351) Raltegravir @ 48wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
52.4% (n=351) vs 53% (n=351) Raltegravir @ 96wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
61% (n=351) vs 60.7% (n=351) Raltegravir @ 48wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
53.6% (n=351) vs 56.4% (n=351) Raltegravir @ 96wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
93.8% (n=290) vs 87.1% (n=139) PI+RTV+FTC/TDF @ 48wk
NCT01475838 · Phase 3 · registry result, not featured evidence
86.9% (n=290) vs 69.8% (n=139) PI+RTV+FTC/TDF @ 96wk
NCT01475838 · Phase 3 · registry result, not featured evidence
93.4% (n=290) vs 88.1% (n=143) NNRTI+FTC/TDF @ 48wk
NCT01495702 · Phase 3 · registry result, not featured evidence
86.6% (n=290) vs 80.4% (n=143) NNRTI+FTC/TDF @ 96wk
NCT01495702 · Phase 3 · registry result, not featured evidence
89.5% (n=353) vs 86.8% (n=355) ATV/r + FTC/TDF @ 48wk
NCT01106586 · Phase 3 · registry result, not featured evidence
83.3% (n=353) vs 82.3% (n=355) ATV/r + FTC/TDF @ 96wk
NCT01106586 · Phase 3 · registry result, not featured evidence
77.6% (n=353) vs 74.6% (n=355) ATV/r + FTC/TDF @ 144wk
NCT01106586 · Phase 3 · registry result, not featured evidence
78.4% (n=74) vs 73.1% (n=78) ATV/r + FTC/TDF @ 192wk
NCT01106586 · Phase 3 · registry result, not featured evidence
86.1% (n=353) vs 84.8% (n=355) ATV/r + FTC/TDF @ 48wk
NCT01106586 · Phase 3 · registry result, not featured evidence
91.5% (n=353) vs 88.5% (n=355) ATV/r + FTC/TDF @ 48wk
NCT01106586 · Phase 3 · registry result, not featured evidence
88.4% (n=112) vs 89.7% (n=58) E/C/F/TDF @ 24wk
NCT01497899 · Phase 2 · registry result, not featured evidence
88.4% (n=112) vs 87.9% (n=58) E/C/F/TDF @ 48wk
NCT01497899 · Phase 2 · registry result, not featured evidence
89.6% (n=48) vs 87% (n=23) Atripla @ 24wk
NCT00869557 · Phase 2 · registry result, not featured evidence
89.6% (n=48) vs 87% (n=23) Atripla @ 48wk
NCT00869557 · Phase 2 · registry result, not featured evidence
89.6% (n=48) vs 87% (n=23) Atripla @ 24wk
NCT00869557 · Phase 2 · registry result, not featured evidence
91.7% (n=48) vs 82.6% (n=23) Atripla @ 48wk
NCT00869557 · Phase 2 · registry result, not featured evidence
CD4+ 239 vs 206 Atripla cells/uL @ 48wk
absolute change · cells/uL
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 26 more results
295 vs 273 Atripla cells/uL @ 96wk
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
321 vs 300 Atripla cells/uL @ 144wk
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
360 vs 328 Atripla cells/uL @ 192wk
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
60 vs 42 Baseline Treatment Regimen (SBR) cells/uL @ 96wk
NCT01815736 · Phase 3 · registry result, not featured evidence
225 vs 200 E/C/F/TDF cells/uL @ 48wk
NCT01797445 · Phase 3 · registry result, not featured evidence
274 vs 260 E/C/F/TDF cells/uL @ 96wk
NCT01797445 · Phase 3 · registry result, not featured evidence
221 vs 212 ATV+RTV+TVD cells/uL @ 48wk
NCT01705574 · Phase 3 · registry result, not featured evidence
48 vs -4 Stay on Baseline Regimen cells/uL @ 24wk
NCT02616783 · Phase 3 · registry result, not featured evidence
56 vs -1 Stay on Baseline Regimen cells/uL @ 48wk
NCT02616783 · Phase 3 · registry result, not featured evidence
235 vs 221 E/C/F/TDF cells/uL @ 48wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
285 vs 271 E/C/F/TDF cells/uL @ 96wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
323 vs 310 E/C/F/TDF cells/uL @ 144wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
138 vs 147 Raltegravir cells/uL @ 48wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
205 vs 198 Raltegravir cells/uL @ 96wk
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
40 vs 32 PI+RTV+FTC/TDF cells/uL @ 48wk
NCT01475838 · Phase 3 · registry result, not featured evidence
61 vs 71 PI+RTV+FTC/TDF cells/uL @ 96wk
NCT01475838 · Phase 3 · registry result, not featured evidence
56 vs 58 NNRTI+FTC/TDF cells/uL @ 48wk
NCT01495702 · Phase 3 · registry result, not featured evidence
83 vs 101 NNRTI+FTC/TDF cells/uL @ 96wk
NCT01495702 · Phase 3 · registry result, not featured evidence
207 vs 211 ATV/r + FTC/TDF cells/uL @ 48wk
NCT01106586 · Phase 3 · registry result, not featured evidence
256 vs 261 ATV/r + FTC/TDF cells/uL @ 96wk
NCT01106586 · Phase 3 · registry result, not featured evidence
280 vs 293 ATV/r + FTC/TDF cells/uL @ 144wk
NCT01106586 · Phase 3 · registry result, not featured evidence
338 vs 340 ATV/r + FTC/TDF cells/uL @ 192wk
NCT01106586 · Phase 3 · registry result, not featured evidence
165 vs 179 E/C/F/TDF cells/uL @ 24wk
NCT01497899 · Phase 2 · registry result, not featured evidence
177 vs 204 E/C/F/TDF cells/uL @ 48wk
NCT01497899 · Phase 2 · registry result, not featured evidence
161 vs 117 Atripla cells/uL @ 24wk
NCT00869557 · Phase 2 · registry result, not featured evidence
240 vs 166 Atripla cells/uL @ 48wk
NCT00869557 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 50 95.2% (n=21) @ 24wk
event count · % of participants
No placebo or comparator arm
NCT02477527 · Phase 4 · registry result, not featured evidence · converted to % from 20 Participants as posted
CD4+ 151 cells/uL @ 24wk
absolute change · cells/uL
No placebo or comparator arm
NCT02477527 · Phase 4 · registry result, not featured evidence
show 2 more results
178 cells/uL @ 24wk
NCT01721109 · Phase 2/3 · registry result, not featured evidence
229 cells/uL @ 48wk
NCT01721109 · Phase 2/3 · registry result, not featured evidence
HIV-1 RNA LT 50 Copies 90.8% (n=447)
responder rate · % of participants
No placebo or comparator arm
NCT02397096 · Phase 3 · registry result, not featured evidence
show 3 more results
94.6% (n=223)
NCT02397096 · Phase 3 · registry result, not featured evidence
93.7% (n=447) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
94.6% (n=223) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
LDL-C -16.54 mg/dL @ 24wk
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.94 mg/dL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
Non-HDL-C Change mg/dL -24.74 mg/dL @ 24wk
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.31 mg/dL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
CD4+ 13.9 cells/uL
absolute change · cells/uL
No placebo or comparator arm
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
show 3 more results
18 cells/uL
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
5.1 cells/uL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
18 cells/uL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
HIV-1 RNA LT 40 Copies 89.7% (n=447)
responder rate · % of participants
No placebo or comparator arm
NCT02397096 · Phase 3 · registry result, not featured evidence
show 3 more results
93.3% (n=223)
NCT02397096 · Phase 3 · registry result, not featured evidence
92.8% (n=447) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
93.3% (n=223) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Ge50 Copies 1.6% (n=447)
responder rate · % of participants
No placebo or comparator arm
NCT02397096 · Phase 3 · registry result, not featured evidence
show 1 more result
1.8% (n=223)
NCT02397096 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 97.2% (n=959) vs 93.1% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
All Participants
NCT01815736 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 20 Copies 93.5% (n=959) vs 90.4% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
All Participants
NCT01815736 · Phase 3 · registry result, not featured evidence

+ 15 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir/lenacapavir (Bixlenvo)'s landscape · Elvitegravir's landscape